Ethris GmbH, a clinical-stage biotechnology company, announced a strategic collaboration with Thermo Fisher Scientific to provide a fully integrated mRNA solution to biopharmaceutical developers. This partnership aims to broaden global access to Ethris’ comprehensive mRNA technology platforms, including its proprietary Stabilized Non-Immunogenic mRNA (SNIM® RNA).
The collaboration combines Ethris’ advanced mRNA technology platforms with Thermo Fisher’s industry-leading end-to-end GMP-compliant manufacturing capabilities. This integration will facilitate the rapid advancement of candidate mRNA medicines from research to clinical proof-of-concept for biopharmaceutical developers.
Ben Castro, Vice President and General Manager, Large Molecule, Drug Substance at Thermo Fisher Scientific, stated that the company is expanding its services to include cutting-edge mRNA manufacturing through this partnership. This move empowers customers to bring life-changing treatments to patients faster and more efficiently, strengthening Thermo Fisher's position in advanced therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.